Nuevas perspectivas de evaluación: buenos resultados en salud en comunidades con atención no satisfactoria

29 gen.

Mireia Espallargues Mireia Espallargues. Responsable Calidad Atención Sanitaria AQuAS

Identificar pacientes con buenos resultados en comunidades con atención no satisfactoria puede ser clave para descubrir factores de éxito

Son varias las iniciativas que abogan por una atención de mayor valor (high-value care) para contribuir a una mayor eficiencia y sostenibilidad de los sistemas de salud. Este valor se interpreta como la obtención de mejores ganancias en salud en relación a los costes, algo que se traduce en un mejor uso de los recursos disponibles (1). La aproximación más tradicional para detectar este valor potencial se ha basado en la identificación de pacientes con un mal estado de salud para poder establecer las posteriores medidas correctoras que conduzcan a un buen resultado.

En un artículo publicado en la revista New England Journal of Medicine, Sequist y Taveras (2) proponen analizar el problema desde una óptica diferente:

  1. Identificar a los pacientes que van bien (“positive outliers“)
  2. Analizar qué factores pueden influir en su buen estado de salud
  3. Diseminar los factores de éxito detectados y hacerlos extensivos al resto del sistema

Continue reading

Noves perspectives d’avaluació: bons resultats en salut en comunitats amb atenció no satisfactòria

29 gen.

Mireia Espallargues Mireia Espallargues. Responsable Qualitat Atenció Sanitària AQuAS

Identificar pacients amb bons resultats en comunitats amb atenció no satisfactòria pot ser clau per descobrir factors d’èxit

Són diverses les iniciatives que advoquen per una atenció de major valor (high-value care) per contribuir a una major eficiència i sostenibilitat dels sistemes de salut. Aquest valor s’interpreta com l’obtenció de millors guanys en salut en relació als costos, quelcom que es tradueix en un millor ús dels recursos disponibles (1). L’aproximació més tradicional per detectar aquest valor potencial s’ha basat en la identificació de pacients amb un mal estat de salut per poder establir les posteriors mesures correctores que condueixin a un bon resultat.

En un article publicat a la revista New England Journal of Medicine, Sequist i Taveras (2) proposen analitzar el problema des d’una òptica diferent:

  1. Identificar els pacients que van bé (“positive outliers“)
  2. Analitzar quins factors poden influir en el seu bon estat de salut
  3. Disseminar els factors d’èxit detectats i fer-los extensius a la resta del sistema.

Continue reading

New perspectives of assessment: good health outcomes in communities with unsatisfactory care

29 gen.

Mireia Espallargues Mireia Espallargues. Head of Healthcare Quality AQuAS

Identifying patients with good results in communities with unsatisfactory care can be the key to finding success factors.

There are several initiatives that advocate a high value care in order to contribute to greater efficiency and sustainability of health systems. This value is interpreted as obtaining better health gains relative to the costs, which translates into better use of available resources (1). The more traditional approach to detect this potential value was based on the identification of patients with poor health in order to establish subsequent remedial measures that lead to a good result.

In an article published in The New England Journal of Medicine, Sequist and Taveras (2) propose to analyze the problem from a different perspective:

  1. Identify patients who are doing good (“positive outliers“)
  2. Analyze what factors may influence their good health
  3. Disseminate the identified success factors and expand them to the rest of the system

To accomplish this, the authors propose a new approach to measure and analyze information. It’s about relating the supply system, the community and the patient in an effort integrated as a strategy with the aim of improving population health. This type of approach strengthens assessment models that AQuAS is applying in areas such as attention to chronicity and integrated health and social care in our country (3-5).

Health determinants and social determinants

According to the authors, the population’s health status is the result of a complex web of interactions between individual patient characteristics and other determinants of health dependent of the area of residence (community). The more evident is that most determinants that affect the health of people would be generated outside the health service delivery system. These factors, that some studies estimated constitute about 80%, have a profound effect on how the patients interact with the system and consequently, the quality of care they receive and their health outcomes.

Thus, the policies and the actions in areas such as housing, employment or social welfare can not be decoupled from assessments on health and from the health system. We must emphasize the need of introducing in the context of public and social policies, the concept of health as an item to be referred to in all its dimensions and evaluated in an integrated manner, together with other social determinants besides the health system (6).

The challenge of evaluating integrated care

Given this new approach it’s necessary to analyze the performance at the community level, usually focused on the area of residence. This analysis will allow provision system to obtain a better understanding of its population and identify where patients are grouped within communities, as well as what are the environmental factors that can affect health outcomes. This represents a quality leap beyond traditional analysis of each service providing system units (hospitals, primary care, care teams, etc.). Among the advantages of this new strategy we must specify the identification of patients who reside in communities where the quality of care and the results are not satisfactory, the detection of promising approaches for patients in these communities and integrating these successful strategies into care plans for the patients.

The definition of the community and the analysis of data for evaluation

To perform this type of assessment it’s necessary to first have a good working definition of “community” as well as a robust infrastructure for data analysis. The second step consists in identifying positive outliers – extreme values with good results- in communities with poor performance or with a high burden of disease – hotspot communities– more specifically, the identification of treated patients with good health outcome in an environment of unsatisfactory service provision and, in particular, those who historically had poor results and who recently improved. Once the success factors are identified, we would move on to the phase of climbing or extending the strategies in the rest of the territory.

In the precise case of the project assessment of the care for chronic diseases, the territories with programs or models of care to chronic diseases seeking greater care integration have been identified, given the large impact on morbidity and mortality and the use of resources caused by a complex chronic population. Consequently, the analysis from this territorial or community vision -taking into account the various healthcare resources and interventions in the territory- has allowed us to identify programs or models that perform better in relation to a number of health result indicators of various quality of care dimensions. This way we can select those that are “outstanding” (good outcomes for patients) and then identify good practices and success factors.

The last step is the integration of these strategies or models with the plans of patient care. Sequist and Taveras cite some other examples of community initiatives that relate to clinical practice (care or welfare services provision) as communicating vessels between the data analysis and the interventions that can be made in various areas.

This analytical approach can have several potential uses and can also be a powerful tool for addressing socioeconomic inequalities in health outcomes; as long as they focus on the differences at the context level, on patients’ membership to a community, on differences in gender, income, or education. Finally the authors mention that, as a prerequisite for a successful implementation, it’s necessary to have a well-defined operational infrastructure in which funding is aligned with the approach of linking the community and the health care.

Similarly, sustainability challenges also occur, as it may be that the service providing system “buys” this concept of factors that historically have been considered outside the area of influence or responsibility of health care. We must also ensure that resources and community interventions are safe and reliable if we want to have the support of professionals to refer patients to these resources as well as determining the most appropriate information updating intervals.

To conclude, we’re looking at an approach that instead of focusing on the “non-compliant” patients, it’s based on the observance and analysis of the best, especially in disadvantaged areas, with the purpose of applying the same keys to success to other territories.

Bibliography

(1) Porter ME. What is value in healthcare?. N Engl J Med. 2010;26:2477-81.

(2) Sequist TD, Taveras EM. Clinic-community linkages for high-value care. N Engl J Med. 2014;371(23):2148-50.

(3) Desenvolupament d’un marc conceptual i indicadors per avaluar l’atenció a la cronicitat. Primer informe. Barcelona: AQuAS; 2013.

(4) Consens i selecció d’indicadors per avaluar l’atenció a la cronicitat. Segon informe. Barcelona: AQuAS; 2013.

(5) Serra-Sutton V, Montané C, Pons JMV, Espallargues M. Avaluació externa de 9 models col•laboratius d’atenció social i sanitària a Catalunya. Barcelona: AQuAS; 2014 (en premsa).

(6) Determinants socials i econòmics de la salut. Efectes de la crisi econòmica en la salut de la població de Catalunya. Barcelona: Observatori del Sistema de Salut de Catalunya. AQuAS; 2014.

Pràctica mèdica: fer molt o fer el necessari?

22 gen.

Joan-PonsJoan MV Pons. Responsable Avaluació AQuAS

La medicina, que és una ciència imperfecte (per això allò de l’art), però també un ofici, ha tendit sempre, potser més pel segon que pel primer, a actuar, a fer quelcom, malgrat això no servís de res, causés un greu perjudici (les sagnies) o, si tenia un efecte beneficiós, aquest no s’aclarís fins molts anys desprès (la mateixa vacuna de la verola de Jenner). Fer, per mostrar que alguna cosa s’ha fet o, encara més, afegint successives intervencions, per mostrar que s’ha fet tot el que es podia fer. Per què aquest afany de fer i fer més cada vegada?

Les raons poden ser diverses. Una, ben simple, lligada a l’ofici i a la pràctica privada (les d’assegurances privades), és que, si et paguen per fer, acabes fent més del necessari, especialment proves diagnòstiques. Sempre amb la millor intenció, per a no oblidar res, recollir la màxima informació, fins i tot per cobrir qualsevol possibilitat remota d’un diagnòstic inversemblant. La medicina defensiva sorgeix d’aquí i es dóna més en els països sobrats d’advocats on el temor al litigi -fonamentat per una casuística creixent- porta a una inflació de proves i més proves. El cas de Dr. Daniel Merenstein, un resident de 3r any, amb un pacient i el PSA és ben notori (el poden llegir a “Winners and Losers“, un article de la Secció A piece of my mindde JAMA).

Continue reading

Práctica médica: ¿hacer mucho o hacer lo necesario?

22 gen.

Joan-PonsJoan MV Pons. Responsable Evaluació AQuAS

La medicina, que es una ciencia imperfecta (por eso lo del arte), pero también un oficio, ha tendido siempre, quizás más por lo segundo que por lo primero, a actuar, a hacer algo, a pesar de que ello no sirviera para nada, causara un grave perjuicio (las sangrías) o, si tenía un efecto beneficioso, éste no se aclarara hasta muchos años después (la misma vacuna de la viruela de Jenner). Hacer, para mostrar que algo se ha hecho o, aún más, añadiendo sucesivas intervenciones, para mostrar que se ha hecho todo lo que se podía hacer. ¿Por qué ese afán de hacer y hacer más cada vez?

Las razones pueden ser varias. Una, bien simple, vinculada al oficio y a la práctica privada (las de seguros privados), es que, si te pagan por hacer, acabas haciendo más de lo necesario, especialmente pruebas diagnósticas. Siempre con la mejor intención, para no olvidar nada, recoger la máxima información, incluso para cubrir cualquier posibilidad remota de un diagnóstico inverosímil. La medicina defensiva surge de aquí y se da más en los países sobrados de abogados donde el temor al litigio -fundamentado por una casuística creciente- lleva a una inflación de pruebas y más pruebas. El caso del Dr. Daniel Merenstein, un residente de 3er año, con un paciente y el PSA, es bien notorio (lo pueden leer en “Winners and Losers”, un artículo de la Sección “A piece of my mind” de JAMA).

Continue reading

Medical practice: do a lot or do just what is needed?

22 gen.

Joan-PonsJoan MV Pons. Head of Evaluation AQuAS

Medicine is an imperfect science (hence it’s an art) but it’s also a craft, and it has always tended, perhaps more for the latter than the former, to want to act, to do something, even to no avail, to the extent that it often causes serious damage (bleeding) or if there is a beneficial effect, it is often not apparent until years later (Jenner’s smallpox vaccine); it acts with the aim of demonstrating that something is being done; moreover, adding successive interventions to show that everything that could be done has been done. Why this desire to act and to do more each time?

There may be several reasons. One of them, a simple one, is linked to the profession itself and to private practice (private insurance) is that; if you’re paid to do it, you end up doing more than required, especially when it comes to diagnostic tests; always with the best of intentions so as not to forget anything, collecting the maximum information with the aim of covering any remote possibility of any unlikely diagnosis. Defensive medicine emerges from here and occurs more in countries with over employed lawyers where the fear of litigation –founded on increasing casuistry- leads to an increasing number of tests. The case of Dr. Daniel Merenstein, a 3 year resident with a patient and the PSA is well known (you can read it at “Winners and Losers”, a JAMA “A piece of my mind” Section article).

It doesn’t stop being a vision that completely neglects the other side of the coin, as if the diagnostic tests were harmless, as if, leaving aside the ionizing radiation from many imaging tests, there was no risk of false positives, false negatives with all their consequences; something similar to countless laboratory tests and biomarkers within reach. There is no perfect test that discriminates with 100% accuracy, nor is human nature itself, always heterogeneous in the extreme (fortunately rare).

It is sufficiently well known that the more variables that are explored, the greater the risk of finding significant results simply by chance; hence the need to correct the level of statistical significance (the famous “p”) in studies with multiple comparisons, such as genetics where they analyse many polymorphisms. Many of these genetic studies of broad scope, generated mostly by technology and its increasingly lower cost, than for a prior hypothesis (authentic fishing expeditions), to rule out pure chance, should apply extremely low values of statistical significance. With the proliferation of imaging tests with a higher and higher resolution, we now speak of those “incidentalomas” to describe those incidental asymptomatic findings exposed while looking for unrelated things; no need to specify the ethical and practical implications that this entails. It’s the same when genetic tests are requested indiscriminately.

There is another reason that can be invoked in order to explain this increased desire to add more than to subtract. Psychologists and economists, academic areas that grow increasingly closer, talk about loss aversion in the sense that we are more affected by the loss (what we had and we no longer have or what we were doing and we are no longer doing) than by the possible gain. That’s why we find it so hard to abandon practices, many simple routines, as one engages autopilot, which do not provide us with any useful information or maybe even worse, may pose a risk and an unnecessary expense.

Excessive medicine, without critical reasoning in acting, can be neither good for patients or for the health system. Don’t forget that when we speak of a health system, we are referring to a universal insurance (for all people) and that this allows us to spread the illness and financial risks of an increasingly expensive health care system. Most of the health budget however, is in the actual hands –the real hands not figuratively speaking- of health professionals when they’re applying tests or prescribing treatments. When the interventions (preventive, diagnostic or therapeutic) for a particular individual do not add value, we are also wasting the shared and limited public resources.

¿Puede un indicador sintético resumir la calidad de la atención prestada por un hospital?

14 gen.

Josep Maria ArgimonJosep Maria Argimon, Director AQuAS

La Central de Resultados tiene la misión de medir, evaluar y difundir los resultados alcanzados, en el ámbito de la asistencia sanitaria, por los diferentes centros del sistema sanitario público. El objetivo es facilitar una mejor toma de decisiones al servicio de la calidad de la atención sanitaria prestada a la ciudadanía. Los resultados en los que se centran los informes incluyen desde la satisfacción de los pacientes hasta la eficiencia en el uso de los recursos. La finalidad última es fomentar un examen interno de los elementos que influyen en los resultados, especialmente en aquellas organizaciones que muestran unos indicadores repetidamente peores que otros. Para incitar a esta tarea, se hace una identificación nominal de las instituciones: no para penalizar, sino para contribuir a mejorar.

Continue reading

Pot un indicador sintètic resumir la qualitat de l’atenció prestada per un hospital?

14 gen.

Josep Maria ArgimonJosep Maria Argimon, Director AQuAS

La Central de Resultats té la missió de mesurar, avaluar i difondre els resultats assolits, en l’àmbit de l’assistència sanitària, pels diferents centres del sistema sanitari públic. L’objectiu és facilitar una millor presa de decisions al servei de la qualitat de l’atenció sanitària prestada a la ciutadania. Els resultats en els que es centren els informes inclouen des de la satisfacció dels pacients fins a l’eficiència en l’ús dels recursos. La finalitat última és fomentar un examen intern dels elements que influeixen en els resultats, especialment en aquelles organitzacions que mostren uns indicadors repetidament pitjors que d’altres. Per a incitar a aquesta tasca, es fa una identificació nominal de les institucions: no pas per penalitzar, sinó per contribuir a millorar.

Continue reading

Can a composite indicator summarize hospital care quality?

14 gen.

Josep Maria ArgimonJosep Maria Argimon, Director AQuAS

The “Central de Resultados” (Results Central) mission is to measure, evaluate and distribute the results achieved by different public health care system centres. The aim is to facilitate better decision-making with regards to the quality of the health care service provided to citizens. The reports feature results from patient satisfaction to the efficiency in the use of resources. The ultimate goal is to foster an internal review of the elements that influence the results, especially in organizations that repeatedly show indicators which are worse than others. To encourage this task, the institutions are nominally identified: not as a punishment but as an incentive to improvement.

Last November the “Agència de Qualitat i Avaluació Sanitària de Catalunya” (AQuAS) released the results for 2013 for hospital and primary care, social care mental health and addiction treatment. The “Central de Resultados” report for hospital care consists of 99 indicators and presents some new features over previous editions. One of the most important is the inclusion of a synthetic indicator of adequacy, in which avoidable hospitalizations for heart failure, diabetes or chronic obstructive pulmonary disease weigh heavily, but where other indicators are also given their due significance. Given its complexity, this new indicator of adequacy was the subject of a detailed explanation during the public presentation of the results and, at the same time, is one of the most featured in the media. In this case, among other centres, the Hospital de la Santa Creu and Sant Pau are examples of the hospitals which should improve this indicator, and thus the media picked on the aforementioned report.

Summarizing the quality of health care provided by a hospital based on a single indicator is very difficult. Now, since the media highlighted the results of this particular indicator, the responsibility for it shall not rest with the messenger but with the issuer, in this case, me. Surely, the communication was poor because if we continue to analyze the report to its full extent we can observe other relevant indicators. For example, the indicator of mortality at 30 days after discharge for selected causes – another novelty of the presented report – shows how a hospital that let’s say has poor results in the synthetic indicator of adequacy, can at the same time have excellent results in the indicator of mortality, such is the case of the Hospital de la Santa Creu and Sant Pau. This is an indicator that is made public in very few public health systems, and some agencies, among which American and British, have promoted its use. Similarly, in other indicators, such as satisfaction with the emergency services, the same Hospital de la Santa Creu and Sant Pau obtained the top positions, as has been well reflected in the media.

We have to keep in mind that the same indicators, despite many efforts, do present some shortcomings, starting with the absence of important outcomes such as the functional ability of patients and their quality of life related to health. But there’s something else that also escapes and that only very specific studies can analyze. I’m talking about the culture of the organization that is largely configured for all the staff that belongs to it; what values they share and the feelings they have towards it. Those organizations that – despite facing serious external problems and discouraging  states of mind, present in any collective, –  believe in the values that inspire their work;  have as their objectives continuous quality improvement; where everyone is involved regardless of age or position (from the manager to the warden), have a better communication and coordination between professional and technical groups;  know without shame or guilt how to examine the causes of their mistakes or failures;  participate and get involved in improvement proposals; all these difficult to collect and analyze features at the organizational and staff level are at the moment of truth, the ones making a difference.

The Results Central is not a perfect instrument, but provides data for evaluating public policies, helping to insure that the established objectives are met and that an efficient allocation of public resources is made. Furthermore, transparency in policy making and accountability in the management of public resources is a requirement of citizenship, a democratic and ethical obligation of governments, and a key element in the development of a country.

The Department of Health, through AQuAS, does not avoid discussing sensitive issues, such as the reports from the Central de Resultados presented last November or the report on the effects of the economic crisis on the population’s health. The press has always addressed these issues with appropriate importance, seriousness and rigor. Therefore, it’s a shame that due to an issuer’s (not a messenger’s) miscommunication they can misinterpret the results and end up detracting from the outstanding work performed by professionals in extremely difficult conditions, so that the thousands of citizens served, cared for and cured on a daily basis know they are in the best possible hands.

Fármacos caros de efectividad escasa: ¿qué estamos dispuestos a perder para poder pagarlos?

8 gen.

Anna Garcia-AltésAnna Garcia-Altés. Responsable del Observatorio del Sistema de Salud de Cataluña

Algunos fármacos biotecnológicos de última generación como Sovaldi (sofosbuvir) para la hepatitis C, o como Avastin (bevacizumab) para el cáncer de mama están poniendo al sistema sanitario en un cruce. Aunque siga sin estar claro el precio de Sovaldi, proyectando el precio obtenido en otros países sobre la prevalencia de la hepatitis C en nuestro contexto, se perfila una cifra escandalosamente elevada. Por su parte, desde su salida al mercado en 2004, Avastin ha sido un fármaco superventas que en pocos años ha obtenido la aprobación para el tratamiento de cinco tipos de tumores y se está investigando en cincuenta demás.

En Estados Unidos se estima que los fármacos biotecnológicos son responsables del 70% del aumento del gasto en farmacia de los últimos años. La relevancia del volumen de negocio queda reflejada muy a menudo en las páginas salmón de los diarios. En este conjunto, se engloban también los fármacos para la artritis reumatoide y la esclerosis múltiple.

Continue reading